Transthyretin Amyloidosis (ATTR)
European Society of Cardiology (ESC) 2024
Congress Details
August 30-September 2, 2024
London, United Kingdom
The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.
All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.
For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.
Congress Materials
Presentation Type
Location
Presenter
Related Materials
Transthyretin Amyloidosis (ATTR)
Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy and Renal Impairment: Analyses From HELIOS-B
Journal of Cardiac Failure
Transthyretin Amyloidosis (ATTR)
Heart Failure Association (HFA) 2026
Transthyretin Amyloidosis (ATTR)
Best Practices and Key Barriers for Amyloidosis Patient Care at US Specialized Amyloidosis Centers: An Analysis by ARC-ASPIRE
Clinical Medicine Insights: Cardiology
Transthyretin Amyloidosis (ATTR)
American Academy of Neurology (AAN) 2026
Transthyretin Amyloidosis (ATTR)
Effect of vutrisiran on components of health status in transthyretin amyloidosis with cardiomyopathy: the HELIOS-B study
European Journal of Heart Failure
Transthyretin Amyloidosis (ATTR)
Efficacy and Safety of Vutrisiran in Patients with Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy: Analysis of the East Asian Subpopulation from HELIOS-A
Neurology and Therapy
